These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23946872)

  • 41. PRMT1 Modulates Processing of Asthma-Related Primary MicroRNAs (Pri-miRNAs) into Mature miRNAs in Lung Epithelial Cells.
    Zhai W; Sun H; Li Z; Li L; Jin A; Li Y; Chen J; Yang X; Sun Q; Lu S; Roth M
    J Immunol; 2021 Jan; 206(1):11-22. PubMed ID: 33239422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Let-7b attenuates cisplatin resistance and tumor growth in gastric cancer by targeting AURKB.
    Han X; Zhang JJ; Han ZQ; Zhang HB; Wang ZA
    Cancer Gene Ther; 2018 Dec; 25(11-12):300-308. PubMed ID: 30237418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
    Zhong S; Li W; Chen Z; Xu J; Zhao J
    Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
    [TBL] [Abstract][Full Text] [Related]  

  • 44. c-Myc Represses Tumor-Suppressive microRNAs, let-7a, miR-16 and miR-29b, and Induces Cyclin D2-Mediated Cell Proliferation in Ewing's Sarcoma Cell Line.
    Kawano M; Tanaka K; Itonaga I; Iwasaki T; Tsumura H
    PLoS One; 2015; 10(9):e0138560. PubMed ID: 26393798
    [TBL] [Abstract][Full Text] [Related]  

  • 45. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.
    Adam L; Zhong M; Choi W; Qi W; Nicoloso M; Arora A; Calin G; Wang H; Siefker-Radtke A; McConkey D; Bar-Eli M; Dinney C
    Clin Cancer Res; 2009 Aug; 15(16):5060-72. PubMed ID: 19671845
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Let-7 miRNA Precursors Co-express with LIN28B in Cervical Cells.
    Zamora-Contreras AM; Alvarez-Salas LM
    Microrna; 2018; 7(1):62-71. PubMed ID: 29336272
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
    Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
    Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Embryonic stem cell microRNAs: defining factors in induced pluripotent (iPS) and cancer (CSC) stem cells?
    Gunaratne PH
    Curr Stem Cell Res Ther; 2009 Sep; 4(3):168-77. PubMed ID: 19492978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines.
    Zhuo L; Liu J; Wang B; Gao M; Huang A
    Oncol Rep; 2013 Feb; 29(2):555-62. PubMed ID: 23229111
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of c-Myc by let-7b mimic reverses mutidrug resistance in gastric cancer cells.
    Yang X; Cai H; Liang Y; Chen L; Wang X; Si R; Qu K; Jiang Z; Ma B; Miao C; Li J; Wang B; Gao P
    Oncol Rep; 2015 Apr; 33(4):1723-30. PubMed ID: 25633261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Upregulated microRNAs in membranous glomerulonephropathy are associated with significant downregulation of IL6 and MYC mRNAs.
    Barbagallo C; Passanisi R; Mirabella F; Cirnigliaro M; Costanzo A; Lauretta G; Barbagallo D; Bianchi C; Pagni F; Castorina S; Granata A; Di Pietro C; Ragusa M; Malatino LS; Purrello M
    J Cell Physiol; 2019 Aug; 234(8):12625-12636. PubMed ID: 30515781
    [TBL] [Abstract][Full Text] [Related]  

  • 52. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of microRNAs in drug-resistant ovarian cancer cells.
    Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
    Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
    [TBL] [Abstract][Full Text] [Related]  

  • 54. microRNAs in uterine sarcomas and mixed epithelial-mesenchymal uterine tumors: a preliminary report.
    Kowalewska M; Bakula-Zalewska E; Chechlinska M; Goryca K; Nasierowska-Guttmejer A; Danska-Bidzinska A; Bidzinski M
    Tumour Biol; 2013 Aug; 34(4):2153-60. PubMed ID: 23558962
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Loss of miR-873 contributes to gemcitabine resistance in triple-negative breast cancer via targeting ZEB1.
    Wang G; Dong Y; Liu H; Ji N; Cao J; Liu A; Tang X; Ren Y
    Oncol Lett; 2019 Oct; 18(4):3837-3844. PubMed ID: 31579087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Overexpression of dicer as a result of reduced let-7 MicroRNA levels contributes to increased cell proliferation of oral cancer cells.
    Jakymiw A; Patel RS; Deming N; Bhattacharyya I; Shah P; Lamont RJ; Stewart CM; Cohen DM; Chan EK
    Genes Chromosomes Cancer; 2010 Jun; 49(6):549-59. PubMed ID: 20232482
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HDAC6 Suppresses Let-7i-5p to Elicit TSP1/CD47-Mediated Anti-Tumorigenesis and Phagocytosis of Hepatocellular Carcinoma.
    Yang HD; Kim HS; Kim SY; Na MJ; Yang G; Eun JW; Wang HJ; Cheong JY; Park WS; Nam SW
    Hepatology; 2019 Oct; 70(4):1262-1279. PubMed ID: 30991448
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential microRNA expression in experimental cerebral and noncerebral malaria.
    El-Assaad F; Hempel C; Combes V; Mitchell AJ; Ball HJ; Kurtzhals JA; Hunt NH; Mathys JM; Grau GE
    Infect Immun; 2011 Jun; 79(6):2379-84. PubMed ID: 21422175
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dose-dependent differential mRNA target selection and regulation by let-7a-7f and miR-17-92 cluster microRNAs.
    Shu J; Xia Z; Li L; Liang ET; Slipek N; Shen D; Foo J; Subramanian S; Steer CJ
    RNA Biol; 2012 Oct; 9(10):1275-87. PubMed ID: 22995834
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer.
    Shekari N; Asghari F; Haghnavaz N; Shanehbandi D; Khaze V; Baradaran B; Kazemi T
    Anticancer Agents Med Chem; 2019; 19(3):304-309. PubMed ID: 30543177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.